{"id":4064,"date":"2025-11-26T19:32:34","date_gmt":"2025-11-26T19:32:34","guid":{"rendered":"https:\/\/sites.manchester.ac.uk\/lydia-becker-institute\/?p=4064"},"modified":"2025-11-26T19:48:06","modified_gmt":"2025-11-26T19:48:06","slug":"radiotherapy-gut-protection-immune-response","status":"publish","type":"post","link":"https:\/\/sites.manchester.ac.uk\/lydia-becker-institute\/2025\/11\/26\/radiotherapy-gut-protection-immune-response\/","title":{"rendered":"Key Immune Cells Found to Protect the Gut During Radiotherapy"},"content":{"rendered":"

[et_pb_section bb_built=”1″ admin_label=”section” fullwidth=”on” next_background_color=”#000000″ global_module=”322″][et_pb_fullwidth_menu global_parent=”322″ _builder_version=”3.0.106″ menu_id=”7″ submenu_direction=”downwards” fullwidth_menu=”off” background_layout=”dark” module_class=”main-navigation” \/][\/et_pb_section][et_pb_section bb_built=”1″ fullwidth=”off” specialty=”on” prev_background_color=”#000000″ next_background_color=”#1d1d1d”][et_pb_column type=”2_3″ specialty_columns=”2″][et_pb_row_inner locked=”off”][et_pb_column_inner type=”4_4″ saved_specialty_column_type=”2_3″][et_pb_post_title _builder_version=”3.0.106″ title=”on” meta=”on” author=”on” date=”on” categories=”on” comments=”on” featured_image=”on” featured_placement=”above” text_color=”dark” text_background=”off” locked=”on” parent_locked=”off” \/][et_pb_text _builder_version=”3.17.6″ background_layout=”light” parent_locked=”off”]<\/p>\n

Radiotherapy (RT) is a vital treatment for many abdominal and pelvic cancers, but it can unintentionally harm healthy tissue \u2014 especially the intestines \u2014 leading to serious side effects that currently have limited treatment options. Although the immune system is known to help repair and regulate damaged tissues, the specific immune processes involved in RT-induced gut toxicity have been unclear.<\/p>\n

In this CRUK RadNet\u00a0Manchester study<\/a>, researchers have uncovered a natural defence mechanism that helps protect the gut during RT. They discovered that a molecule called CCR2<\/strong> plays a key role in recruiting monocytes<\/strong> \u2014 immune cells that travel to the intestine after radiation exposure. Once there, these monocytes trigger a chain of protective immune signals, including the release of IL-17<\/strong>, a molecule that helps maintain the integrity of the intestinal barrier.<\/p>\n

The team found that when CCR2 was missing, mice experienced worse symptoms: increased weight loss, greater intestinal leakiness, and more severe tissue damage. However, transferring monocytes into these mice helped reverse many of these effects, boosting IL-17 levels and improving gut protection. These results highlight the importance of CCR2-driven monocyte recruitment in limiting radiation-induced intestinal injury.<\/p>\n

To uncover these mechanisms, the researchers used a CT-guided model of localised intestinal irradiation, along with advanced techniques such as single-cell RNA sequencing and flow cytometry. They also analysed serum samples from cancer patients undergoing RT to link their findings to human biology.<\/p>\n

\n

\u201cThese findings give us new insight into the off-target effects of radiotherapy, which can be a major challenge for patients.<\/em><\/p>\n

 <\/p>\n

If we can better target radiotherapy and limit these side effects, patients may be able to receive higher, more effective doses to treat and remove their cancers.\u201d<\/em><\/p>\n

 <\/p>\n

Dr Doug Dyer<\/a>\u00a0–\u00a0Co-author<\/strong><\/p>\n<\/blockquote>\n

CRUK RadNet Manchester<\/a> is a Radiation Research Centre of Excellence and works in collaboration with The Christie NHS Foundation Trust, The University of Manchester and the Lydia Becker Institute of Immunology and Inflammation as part of their Radiotherapy and Immune Cell Interactions research activities<\/a>.<\/p>\n